Using Alternative Data to Evaluate Pharmaceutical Pipelines

Keava Low, Research Analyst (London)

Neudata Intelligence
Post feature

We summarise the key findings of a research paper co-authored by a pharmaceutical data provider. Using Takeda Pharmaceutical’s FY 2017 Q4 pipeline as an example, we also provide a brief overview of how phase transition data can be used by investors to gain a better understanding of which drugs are most likely to be approved by the FDA and to analyse the health of a pharmaceutical company’s pipeline.

Neudata quick view

This research paper analyses individual drug program phase transitions over a ten year period in order to determine FDA approval success rates for investigational drugs. Research is conducted using data sourced from the pharmaceutical data provider shown below that tracks and analyses

Request a Neudata trial

We'd like to know a bit more about you and your business, so we can deal with your request efficiently.
We take your privacy seriously and handle your personal data in line with our privacy statement.

We use your email address as part of allowing you access to your account and in order to provide you details with our products that might be of interest to you